Widespread GLP-1 adoption ushered in a wave of mainstream peptide experimentation if semaglutide and tirzepatide opened the door, BPC-157, TB-500, ipamorelin, CJC-1295, MOTS-C, and GHK-Cu ran through it shortly thereafter
Inflammopharmacology 25:439449 Novinscak T, Brcic L, Staresinic M, Jukic I, Radic B, Pevec D, Mise S, Tomasovic S, Brcic I, Banic T (2008) Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat
Space away from other medications by at least 1 hour
Abstract Glucagon-like peptide-1 (GLP-1) and its receptor agonists (GLP-1RAs) are well-established therapies for metabolic conditions such as type 2 diabetes and obesity due to their ability to enhance insulin secretion, promote weight loss, and regulate blood glucose levels